| 1 | Багрова С. Г., Басин Е.М., Валиев А.К., Деньгина Н.В., Копп М.В., Кутукова С.И. и соавт. Профилактика и лечение патологии костной ткани при злокачественных новообразованиях. Злокачественные опухоли : Практические рекомендации RUSSCO #3s2, 2022 ( том 12 ). 40–54. |
| 2 | Ingangi V.,Minopoli M.,Ragone C.et al.Role of microenvironment on the fate of disseminating cancer stem cells. Front Oncol. 2019; 9: 82 |
| 3 | D'Oronzo S.,Coleman R.,Brown J.,Silvestris F. Metastatic bone disease: pathogenesis and therapeutic options: up-date on bone metastasis management. J Bone Oncol. 2019; 15: 004 |
| 4 | Coleman RE, Brown JE, Holen I. Bone metastases. In: Clinical Oncology – 6th edition, Niederhuber J.E., Armitage J.O., Doroshaw JH, Kastan M.B. & Tepper JE. (eds) Chapter 51; 809-830, 2019, Elsevier, Churchill Livingstone: Philadelphia |
| 5 | Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12: 6243s-6249s |
| 6 | von Moos R. Costa L.Gonzalez-Suarez E.et al.Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody.Cancer Treat Rev. 2019; 76: 57-67 |
| 7 | Coleman R, et al. Bone health in cancer: ESMO Clinical Practice Guidelines Ann Oncol 2020:S0923–7534(20)39995–6. |
| 8 | Bonakdarpour A., Reinus W.R., Khurana J.S. Editors. Diagnostic Imaging of Musculoskeletal Diseases. A Systematic Approach // Springer Science+Business Media, LLC. – 2010. – P.302-308 |
| 9 | Galasko CS: The value of scintigraphy in malignant disease. Cancer Treat Rev 2:225-272, 1975 |
| 10 | Лишманов Ю.Б., Чернов В.И. Радионуклидная диагностика для практических врачей. – Томск, 2004. – С.280- 285 |
| 11 | Galasko CS, Doyle FH: The detection of skeletal metastases from mammary cancer: A regional comparison between radiology and scintigraphy. Clin Radiol 23:295-297, 1972 |
| 12 | Citrin D.L., Bessent R.G., Greig W.R. A comparison of the sensitivity and ac-curacy of the 99m Tc-phosphate bone scan and skeletal radiograph in the diagnosis of bone metastases // Clin Radiol. — 1977. — Vol. 28. —P. 107-117 |
| 13 | Vogel CL, Schoenfelder J, Shemano I et al. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 1995; 13: 1123–1128. DOI: 10.1200/JCO.1995.13.5.1123 |
| 14 | Coleman RE, Mashiter G, Whitaker KB et al. Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med 1988; 29: 1354–1359 |
| 15 | Yang HL, Liu T, Wang XM, Xu Y, Deng SM. Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. European Radiology 2011; 21(12): 2604-2617. DOI: 10.1007/s00330-011-2221-4 |
| 16 | Shie P., Cardarelli R., Brandon D., Erdman W., Abdulrahim N. Meta-analysis: Comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med. 2008;33:97–101. DOI: 10.1097/RLU.0b013e31815f23b7 |
| 17 | Broski S.M.,Young J.R.,Kendi A.T., Subramaniam R.M. Skeletal metastasis evaluation: value and impact of PET/computed tomography on diagnosis, management and prognosis. PET Clin. 2019; 14: 103-120 |
| 18 | Chang MC, Chen JH, Liang JA, Lin CC, Yang KT, Cheng KY, Yeh JJ, Kao CH. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer. Acad Radiol. 2012 Mar;19(3):349-57. doi: 10.1016/j.acra.2011.10.018. |
| 19 | Zhou J, Gou Z, Wu R, Yuan Y, Yu G, Zhao Y. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Skeletal Radiol. 2019 Dec;48(12):1915-1924. doi: 10.1007/s00256-019-03230-z |
| 20 | Umbehr M.H., Müntener M., Hany T., Sulser T., Bachmann L.M. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013 Jul;64(1):106-17. doi: 10.1016/j.eururo.2013.04. 019 |
| 21 | Woolf D.K., Padhani A.R., Makris A. Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care? Annals of Oncology 26: 1048–1057, 2015 DOI:https://doi.org/10.1093/annonc/mdu558 |
| 22 | Hamaoka T, Costelloe CM, Madewell 8JE et al. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer 2010; 102: 651–657 |
| 23 | Criscitiello, C., André, F., Thompson, A.M., De Laurentiis, M., Esposito, A., et al.. Biopsy confirmation of metastatic sites in breast cancer patients: Clinical impact and future perspectives. Breast Cancer Res. 2014, 16, 205 doi: 10.1186/bcr3630 |
| 24 | Wahl R.L., Jacene H., Kasamon Y. et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors // J. Nucl. Med. 2009. Vol. 50. Suppl 1. P. 122S–50S |
| 25 | Veltri, A.; Bargellini, I.; Giorgi, L.; Almeida, P.A.M.S.; Akhan, O. CIRSE Guidelines on Percutaneous Needle Biopsy (PNB). Cardiovasc. Interv. Radiol. 2017, 40, 1501–1513. DOI: 10.1007/s00270-017-1658-5 |
| 26 | NCCN Guidelines Version 1.2022- Adult Cancer Pain https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1413 |
| 27 | Himelstein AL, Foster JC, Khatcheressian JL, et al: Effect of longer-Interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: A randomized clinical trial. JAMA 317:48, 2017 |
| 28 | Benjamin A.Gartrella,RobertColeman,bEleniEfstathioucKarimFizazid Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options European Urology, Volume 68, Issue 5, November 2015, Pages 850-858 |
| 29 | O’Carrigan B, Wong MH, Willson ML, et al: Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 10:CD003474, 2017 |
| 30 | Barrett-Lee P, Casbard A, Abraham J, et al: Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metas- tases from breast cancer: A randomised, open label, non- inferiority phase 3 trial. Lancet Oncol 15:114, 2014 |
| 31 | de Groot A.F.,Appelman-Dijkstra N.M.,van der Burg S.H.,Kroep J.R.The anti-tumor effect of RANKL inhibition in malignant solid tumors – a systematic review.Cancer Treat Rev. 2018; 62: 18-28 |
| 32 | Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME: Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis. Cancer Treat Rev 39: 97, 2013 |
| 33 | Wang X, Yang KH, Wanyan P, Tian JH: Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta- analysis of randomized controlled trials. Oncol Lett 7:2014 |
| 34 | Henry D, Vadhan-Raj S, Hirsh V, et al: Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: An analysis of 2017 data from patients with solid tumors. Support Care Cancer 22:679, 2014 |
| 35 | Stopeck A.T.,Lipton A.,Body J.J.,et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.J Clin Oncol. 2010; 28: 5132-5139 |
| 36 | Cummings S.R.,Ferrari S.,Eastell R.,et al.Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018; 33: 190-198 |
| 37 | Otto S., Pautke C.,Van den Wyngaert T.et al. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018; 69: 177-187 |
| 38 | Aghaloo T, Hazboun R, Tetradis S: Pathophysiology of osteonecrosis of the jaws. Oral Maxillofac Surg Clin North Am 27:489, 2015 |
| 39 | Salvatore L. Ruggiero, Thomas B. Dodson, Tara Aghaloo, Eric R. Carlson, Brent B. Ward, Deepak Kademani, American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update, Journal of Oral and Maxillofacial Surgery, Volume 80, Issue 5, 2022, Pages 920-943, ISSN 0278-2391 |
| 40 | Boquete-Castro A, Gomez-Moreno G, Calvo-Guirado JL, et al: Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res 27: 367, 2016 |
| 41 | Sternlicht H, Glezerman IG. Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag 2015;11:1779–88. |
| 42 | Sternlicht H, Glezerman IG. Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag 2015;11:1779–88 |
| 43 | Rosner MH, Dalkin AC. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol 2012;7:1722–1729. |
| 44 | Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005; 352:373–379. |
| 45 | Diel IJ, Body JJ, Stopeck AT, et al. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Eur J Cancer 2015;51:1467–75. |
| 46 | Валиев, А.К. Хирургическое лечение метастатического поражения костей / А.К. Валиев, Э.Р. Мусаев, Е.А. Сушенцов, М.Д. Алиев // Практическая онкология. – 2011. – Т. 12, № 3. – С. 112-116 |
| 47 | В.М.Моисеенко. Паллиативное лечение больных солидными опухолями с метастатическим поражением костей. Практическая онкология №1 (5), стр 36-37; 2001 |
| 48 | Weiss KR, Bhumbra R, Biau DJ et al. Fixation of pathological humeral fractures by the cemented plate technique. J Bone Joint Surg Br 2011; 93: 1093-1097 |
| 49 | Goetz MP, Callstrom MR, Charboneau JW, et al. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol. 2004;22:300–306 |
| 50 | Health Quality Ontario. Vertebral Augmentation Involving Vertebroplasty or Kyphoplasty for Cancer-Related Vertebral Compression Fractures: A Systematic Review. Ont Health Technol Assess Ser. 2016; 16(11): 1-202 |
| 51 | Rose, P.S. Minimally invasive treatment of spinal metastases: techniques / P.S. Rose, M.B. Dekutoski, M.J. Clarke // Int. J. Surg. Oncol. – 2011. – Vol. 2011. – P. 1-6. |
| 52 | A. Mesfin, D.M.H. El, A. Jain, H. Hassanzadeh, K.M. Kebaish, Total en bloc spondylectomy for primary and metastatic spine tumors, Orthopedics 38 (11) (2015) 995–1000 |
| 53 | Huang, H. Wei, W. Cai, et al., Total en bloc spondylectomy for solitary metastatictumors of the fourth lumbar spine in a posterior-only approach, World Neurosurg (2018). |
| 54 | Patchell, R.A. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomized trial / R.A. Patchell, P.A. Tibbs, W.F. Regine et al. // Lancet. – 2005. – Vol. 366, N 9486. – P. 643-648. |
| 55 | Lutz S, Balboni T, Jones J, Lo S, et al. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Practical Radiation Oncology (2017) 7, 4-12; |
| 56 | Chow E, Zeng L, Salvo N, et al. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2012;24:112-124. |
| 57 | Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011; 79(4): 965-976 |
| 58 | Huisman M, van den Bosch MA, Wijlemans JW, et al. Effectiveness of reirradiation for painful bone metastases: A systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 012;84:8-14 |
| 59 | Handkiewicz-Junak D, Poeppel TD, Bodei L, et al. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. Eur J Nucl Med Mol Imaging. 2018 May;45(5):846-859. |
| 60 | Baczyk M, Milecki P, Pisarek M, et al. A prospective randomized trial: A comparison of the analgesic effect and toxicity of 153Sm radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy (EBRT) among metastatic castrate resistance prostate cancer (mCRPC) patients with painful bone metastases. Neoplasma. 2013;60:328-333 |
| 61 | C.S. Higano, B. Tombal ,K.Miller, F.Saad, O. Sartor , et al/ Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts with metastatic castrationresistant prostate cancer (mCRPC) Annals of Oncology.2018/ Volume 29 | Supplement 8 | doi:10.1093/annonc/mdy284 viii289. |
| 62 | Sartor O, Hoskin P, Bruland OS. Targeted radio-nuclide therapy of skeletal metastases. Cancer Treat Rev 2013; 39: 18-26 |
| 63 | Tang BM, Eslick GD, Nowson C et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370: 657-666. |